Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 1.75B -10.8% |
| Revenue (ttm) | 899.11M +20.7% |
| Net Income | 145.62M -4.7% |
| EPS | 2.48 -5.4% |
| Shares Out | 57.89M |
| PE Ratio | 12.16 |
| Forward PE | 8.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 431,486 |
| Open | 30.51 |
| Previous Close | 30.49 |
| Day's Range | 29.96 - 30.81 |
| 52-Week Range | 25.52 - 40.87 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 44.36 (+47.13%) |
| Earnings Date | May 7, 2026 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P... [Read more]
Financial Performance
In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $44.36, which is an increase of 47.13% from the latest price.
News
Harmony Biosciences Holdings Transcript: AGM 2026
The meeting confirmed a quorum, elected four directors to serve until 2029, ratified the auditor for 2026, and approved executive compensation. A Q&A session addressed stockholder questions relevant to the agenda.
Harmony Biosciences price target raised to $29 from $25 at Truist
Truist raised the firm’s price target on Harmony Biosciences (HRMY) to $29 from $25 and keeps a Hold rating on the shares after meeting with the company’s management team. Wakix…
Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B
07:39 EDT Harmony Biosciences (HRMY) backs FY26 revenue view $1B-$1.04B, consensus $1.02B
Harmony Biosciences Holdings Earnings Call Transcript: Q1 2026
Q1 net revenue grew 17% year-over-year to $215.4M, driven by WAKIX demand and robust pipeline progress. Full-year guidance of $1–$1.04B was reiterated, with strong cash reserves and a multi-layered IP strategy supporting long-term growth.
Harmony Biosciences Holdings Slides: Q1 2026
Harmony Biosciences Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Harmony Biosciences Holdings Earnings release: Q1 2026
Harmony Biosciences Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Harmony Biosciences Holdings Quarterly report: Q1 2026
Harmony Biosciences Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance...
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the ...
Harmony Biosciences price target raised to $72 from $62 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Harmony Biosciences (HRMY) to $72 from $62 and keeps an Outperform rating on the shares. The firm attributes yesterday’s share…
Harmony patent litigation update ‘major positive,’ says Mizuho
Mizuho analyst Graig Suvannavejh says the firm has learned of a new patent lawsuit filed by Harmony Biosciences (HRMY) against AET Pharma, the sole remaining generic challenger that has yet…
Harmony extends rally, shares up 16% after Mizuho research note
Harmony Biosciences (HRMY) shares in midday trading are up $4.88 to $34.35.
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-...
Harmony Biosciences appoints Reicin as Chief Financial Officer
Harmony Biosciences (HRMY) Holdings announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony’s continued focus on strategic growth, financial str...
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting...
Harmony Biosciences Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference
Strong WAKIX growth and expanded sales teams support a $1B+ revenue target, while new pitolisant formulations and a potent orexin program drive pipeline expansion. Settlements secure exclusivity, and robust cash reserves enable strategic business development across CNS indications.
Harmony Biosciences Holdings Proxy statement: Proxy filing
Harmony Biosciences Holdings filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Harmony Biosciences Holdings Proxy statement: Proxy filing
Harmony Biosciences Holdings filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Harmony Biosciences appoints Anastasiou as Chief Operating Officer
Harmony Biosciences (HRMY) announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and…
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Dir...
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual...
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leeri...
Harmony Biosciences price target lowered to $30 from $31 at Deutsche Bank
Deutsche Bank analyst David Hoang lowered the firm’s price target on Harmony Biosciences (HRMY) to $30 from $31 and keeps a Hold rating on the shares. The firm updated the…
Harmony Biosciences price target lowered to $36 from $46 at UBS
UBS analyst So Youn Shim lowered the firm’s price target on Harmony Biosciences (HRMY) to $36 from $46 and keeps a Neutral rating on the shares. The stock rebounded 5%…
Harmony Biosciences price target lowered to $28 from $32 at BofA
BofA lowered the firm’s price target on Harmony Biosciences (HRMY) to $28 from $32 and keeps an Underperform rating on the shares. The firm’s lowered target mainly reflects more conservative…